{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T16:55:53Z","timestamp":1772816153723,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,17]],"date-time":"2013-08-17T00:00:00Z","timestamp":1376697600000},"content-version":"vor","delay-in-days":3395,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2004,5]]},"DOI":"10.1016\/s1535-6108(04)00122-9","type":"journal-article","created":{"date-parts":[[2004,5,24]],"date-time":"2004-05-24T11:03:40Z","timestamp":1085396620000},"page":"411-415","source":"Crossref","is-referenced-by-count":59,"title":["Predictive factors for epidermal growth factor receptor inhibitors\u2014The bull's-eye hits the arrow"],"prefix":"10.1016","volume":"5","author":[{"given":"Janet E.","family":"Dancey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S1535-6108(04)00122-9_BIB1","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1378\/chest.112.6.1474","article-title":"Cigarette smoking and histologic type of lung cancer in men","volume":"112","author":"Barbone","year":"1997","journal-title":"Chest"},{"key":"10.1016\/S1535-6108(04)00122-9_BIB2","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1200\/JCO.2002.03.100","article-title":"Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types","volume":"20","author":"Baselga","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S1535-6108(04)00122-9_BIB3","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/1521-1878(200008)22:8<697::AID-BIES3>3.0.CO;2-1","article-title":"The EGF receptor","volume":"22","author":"Carpenter","year":"2000","journal-title":"Bioessays"},{"key":"10.1016\/S1535-6108(04)00122-9_BIB4","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1158\/1078-0432.CCR-03-0564","article-title":"United States Food and Drug Administration Drug Approval summary","volume":"10","author":"Cohen","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/S1535-6108(04)00122-9_BIB5","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/BF01141022","article-title":"Nobel lecture. Epidermal growth factor","volume":"6","author":"Cohen","year":"1986","journal-title":"Biosci. Rep."},{"key":"10.1016\/S1535-6108(04)00122-9_BIB6","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/307521a0","article-title":"Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences","volume":"307","author":"Downward","year":"1984","journal-title":"Nature"},{"key":"10.1016\/S1535-6108(04)00122-9_BIB7","first-page":"2164","article-title":"Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo","volume":"51","author":"Ekstrand","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/S1535-6108(04)00122-9_BIB8","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","article-title":"Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer","volume":"21","author":"Fukuoka","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S1535-6108(04)00122-9_BIB9","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1200\/JCO.2004.08.001","article-title":"Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer","volume":"22","author":"Giaccone","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S1535-6108(04)00122-9_BIB10","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2002.03.038","article-title":"Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors","volume":"20","author":"Herbst","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S1535-6108(04)00122-9_BIB11","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2004.07.215","article-title":"Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer","volume":"22","author":"Herbst","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S1535-6108(04)00122-9_BIB12","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1200\/JCO.2003.11.069","article-title":"Epidermal growth factor receptor in non-small-cell lung carcinomas","volume":"21","author":"Hirsch","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S1535-6108(04)00122-9_BIB13","first-page":"2316","article-title":"Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells","volume":"9","author":"Janmaat","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/S1535-6108(04)00122-9_BIB14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0169-5002(95)00566-8","article-title":"Aspects of the epidemiology of lung cancer in smokers and nonsmokers in the United States","volume":"15","author":"Kabat","year":"1996","journal-title":"Lung Cancer"},{"key":"10.1016\/S1535-6108(04)00122-9_BIB15","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","article-title":"Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer","volume":"290","author":"Kris","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/S1535-6108(04)00122-9_BIB16","doi-asserted-by":"crossref","unstructured":"Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., Harris, P.L., Haserlat, S.M., Supko, J.G., Haluska, F.G., et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to Gefitinib. N. Engl. J. Med. Published online April 29, 2004. 10.1056\/NEJMoa040938","DOI":"10.1056\/NEJMoa040938"},{"key":"10.1016\/S1535-6108(04)00122-9_BIB17","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/sj.bjc.6601565","article-title":"Filter cigarette smoking and lung cancer risk; a hospital-based case\u2013control study in Japan","volume":"90","author":"Marugame","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/S1535-6108(04)00122-9_BIB18","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1183\/09031936.02.00296502","article-title":"The role of EGF-R expression on patient survival in lung cancer","volume":"20","author":"Meert","year":"2002","journal-title":"Eur. Respir. J."},{"key":"10.1016\/S1535-6108(04)00122-9_BIB19","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2004.08.158","article-title":"Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer","volume":"22","author":"Miller","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S1535-6108(04)00122-9_BIB20","first-page":"11","article-title":"Activated Akt expression has significant correlation with EGFR and TGF-alpha expressions in stage I NSCLC","volume":"24","author":"Mukohara","year":"2004","journal-title":"Anticancer Res."},{"key":"10.1016\/S1535-6108(04)00122-9_BIB21","first-page":"567","volume":"31","author":"Nishiwaki","year":"2004","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1016\/S1535-6108(04)00122-9_BIB22","doi-asserted-by":"crossref","unstructured":"Paez, J.G., Janne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F.J., Lindeman, N., Boggon, T.J., et al. (2004). EGFR mutations in lung cancer: Correlation with clinical response to Gefitinib therapy. Science. Published online April 29, 2004. 10.1126\/science.1099314","DOI":"10.1126\/science.1099314"},{"key":"10.1016\/S1535-6108(04)00122-9_BIB23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/geno.2000.6341","article-title":"Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms","volume":"71","author":"Reiter","year":"2001","journal-title":"Genomics"},{"key":"10.1016\/S1535-6108(04)00122-9_BIB24","first-page":"515","article-title":"Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression","volume":"3","author":"Rusch","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/S1535-6108(04)00122-9_BIB25","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1126\/science.1082024","article-title":"Signal transduction. Autoinhibition control","volume":"300","author":"Schlessinger","year":"2003","journal-title":"Science"},{"key":"10.1016\/S1535-6108(04)00122-9_BIB26","first-page":"1531","article-title":"Activation of the EGF receptor by insertional mutations in its juxtamembrane regions","volume":"11","author":"Sorokin","year":"1995","journal-title":"Oncogene"},{"key":"10.1016\/S1535-6108(04)00122-9_BIB27","first-page":"1193","article-title":"Smoking and lung cancer risk in American and Japanese men","volume":"10","author":"Stellman","year":"2001","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/S1535-6108(04)00122-9_BIB28","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1054\/bjoc.2001.1722","article-title":"Dietary factors and lung cancer risk in Japanese","volume":"84","author":"Takezaki","year":"2001","journal-title":"Br. J. Cancer"},{"key":"10.1016\/S1535-6108(04)00122-9_BIB29","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/S1535-6108(04)00122-9_BIB30","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/jjco\/hyg019","article-title":"A comparison of trends in the incidence rate of lung cancer by histological type in the Osaka Cancer Registry, Japan and in the Surveillance, Epidemiology and End Results Program, USA","volume":"33","author":"Yoshimi","year":"2003","journal-title":"Jpn. J. Clin. Oncol."}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610804001229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610804001229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,8]],"date-time":"2019-02-08T06:27:03Z","timestamp":1549607223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610804001229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["S1535610804001229"],"URL":"https:\/\/doi.org\/10.1016\/s1535-6108(04)00122-9","relation":{},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2004,5]]}}}